Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Activiomics Ltd.. (3/14/11). "Press Release: Biomarker Specialist Activiomics Receives Investment from IP Group plc. Investment in Queen Mary, University of London Spin-out to Fund Growth Strategy".

Region Region United Kingdom (GB)
Organisation Organisation Activiomics Ltd.
  Group Retroscreen Virology (Group)
Products Product TIQUAS technology (Targeted In-depth Quantification of cell Signalling)
  Product 2 venture capital
Index terms Index term Activiomics–SEVERAL: investment, 201103 investment >£500k by IP Group + IP Venture Fund + Activiomics’ management
  Index term 2 Activiomics–IP Group: investment, 201103 investment >£500k by IP Group + IP Venture Fund + Activiomics’ management
Persons Person Warne, Mark (IP Group 201411 Healthcare Portfolio Director + Activiomics 201004 Interim CEO)
  Person 2 Cutillas, Pedro (Activiomics 201004 scientific co-founder)

Activiomics Ltd., the developer of innovative technologies for transforming the way in which drug biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled, is pleased to announce that it has received investment of over £500,000 led by IP Group plc (LSE: ipo) ("IP Group"), the developer of intellectual property based businesses.

Activiomics' proprietary technology has broad application in the area of biomarker and drug discovery in a number of disease areas, including oncology and inflammation. Since its incorporation in February 2010, the company has demonstrated the value of its technology through revenue generating partnerships with big pharma, including GlaxoSmithKline, UCB and Genentech.

Mark Warne, Activiomics' CEO on secondment from IP Group, said: "Better prediction of clinical outcomes is vital to improve drug approval numbers." Pointing to recent high profile clinical trial failures, he continued "Biomarkers are a route to improving that prediction. That said, proving that new markers increase predictability in development and treatment is critical. Our technology will enable this and significantly contribute towards pharma and biotech's efforts to gain timely approvals by regulatory authorities".

Investors in the funding round included IP Group, IP Venture Fund, (a venture capital fund managed by IP Group) and members of Activiomics' management. The funds raised will strengthen Activiomics' ability to grow its partnerships with pharmaceutical and biotechnology companies and to pursue the identification of novel predictive and prognostic markers in oncology using its proprietary label-free technology on exclusively accessed human tissue samples. The company will have access to state of the art mass spectrometry facilities while being advised by world class scientists, including its scientific founders: world leading expert in PI3K signalling Bart Vanhaesebroeck and pioneer in the field of label free proteomics Pedro Cutillas.

For further information, please contact:

Activiomics Limited
Mark Warne, CEO +44 (0) 845 5195 091

IP Group
Greg Smith, Group Financial Controller +44 (0) 20 7444 0050

Notes for editors

About Activiomics

Activiomics Ltd. has developed a groundbreaking and patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled.

Activiomics' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of phosphorylation sites. Phosphorylation is critical mediator all cellular processes and hence sites of phosphorylation represent an important class of novel biomarkers. Activiomics' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics.

Activiomics commercialises its technology by partnering directly with pharmaceutical and biotechnology companies on bespoke programmes of work. In addition it is using its TIQUAS technology in combination with exclusively accessed primary breast and kidney cancer samples to generate proof of concept data and high value data packages for novel predictive and prognostic markers programmes.

About IP Group

IP Group is an intellectual property (IP) commercialisation company that specialises in commercialising university technology. Founded in 2001, IP Group listed on AIM in October 2003 and moved to the Official List in June 2006. IP Group has formed long-term partnerships with ten universities - the University of Oxford, King's College London, CNAP/University of York, the University of Leeds, the University of Bristol, the University of Surrey, the University of Southampton, Queen Mary (University of London), the University of Bath and the University of Glasgow.

For more information, please visit our website at

Record changed: 2015-08-01


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

More documents for Retroscreen Virology (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Männer Ballett 650x80px

» top